Clinical trials sponsored by Shandong Suncadia Medicine Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by Shandong Suncadia Medicine Co., Ltd.

• A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
  NCT07229950 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
  NCT07024173 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction
  NCT07269717 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · 1 location
• A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
  NCT07419828 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
  NCT07349069 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis
  NCT07351968 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
  NCT07389733 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
  NCT07354022 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
  NCT06679036 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
  NCT07589569 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
  NCT06167694 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
  NCT07528027 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 4 locations
• Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
  NCT06222879 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity
  NCT06820099 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations

Common questions

How many trials is Shandong Suncadia Medicine Co., Ltd. recruiting for?

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 14 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.